Janet Woodcock and Pharmaceutical Supply Chain

Selected healthcare news for the person - Janet Woodcock, and the healthcare topic - Pharmaceutical Supply Chain We have 6 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
6/15/2020 Faulty Prescription: Why a “Buy American” Approach for Drugs and Medical Products Is the Wrong Solution ... Buy American Act’s intent for Department of Defense (DoD) and Department of Veterans Affairs (VA) purchases. [11] The Protecting our Pharmaceutical Supply Chain From China Act would go much further by “prohibiting pharmaceutical purchases from ... become increasingly reliant on foreign suppliers for active pharmaceutical ingredients. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER), testified before Congress that (as of August 2019), only 28 percent of ...
10/30/2019 Low generic-drug prices exacerbate drug shortages: FDA Modern Healthcare Print More drugs are in short supply for longer periods of time due to a fundamentally flawed pharmaceutical supply chain, according to a new report. The number of ongoing drug shortages has increased from 2017 ... quality problems. "We feel there is market failure here," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said during a House Energy and Commerce Committee hearing Wednesday on the pharmaceutical ...
7/2/2019 FDA warns repackers distributing pharmaceutical ingredients, including opioids, for putting consumers at risk with significant violations of manufacturing quality standards | Markets Insider Business Insider ... Spectrum Laboratory Products, Inc., for significant violations of current good manufacturing practice (CGMP) requirements. "Repackers play a role in the pharmaceutical supply chain, and some distribute bulk API to drug manufacturers and pharmacy compounders. The ... of the opioid crisis for those who handle opioids," said Janet Woodcock , M.D., director of the FDA's Center for Drug Evaluation and Research. "The supply chain issues we have found in the API repacking industry ...
7/2/2019 FDA warns repackers distributing pharmaceutical ingredients, including opioids, for putting consumers at risk with significant violations of manufacturing quality standards PR Newswire ... Spectrum Laboratory Products, Inc., for significant violations of current good manufacturing practice (CGMP) requirements. "Repackers play a role in the pharmaceutical supply chain, and some distribute bulk API to drug manufacturers and pharmacy compounders. The ... of the opioid crisis for those who handle opioids," said Janet Woodcock , M.D., director of the FDA's Center for Drug Evaluation and Research. "The supply chain issues we have found in the API repacking industry ...
5/18/2019 FDA defends oversight amid questions of safety of generic drugs made in India and China Yahoo News ... Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. " The FDA faces an enormous challenge policing a global pharmaceutical supply chain in which at least 80 percent of drug ingredients and 40 percent of finished drugs sold in the USA are made or handled at thousands of factories overseas. In 2012, Congress directed the agency to prioritizes inspections of domestic and overseas inspections based on a drug ...
5/18/2019 Generic drug safety questioned amid valsartan recalls Yahoo News ... Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. " The FDA faces an enormous challenge policing a global pharmaceutical supply chain in which at least 80 percent of drug ingredients and 40 percent of finished drugs sold in the USA are made or handled at thousands of factories overseas. In 2012, Congress directed the agency to prioritizes inspections of domestic and overseas inspections based on a drug ...